Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients
Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
The survival of adult patients with standard-risk acute lymphoblastic leukemia(ALL) need to
improve. We want to compare the efficacy of haplo-identical hematopoietic stem cell
transplantation (HSCT) with chemotherapy for adult(age:18-39 years old) ALL patients in first
phase of complete remission (CR1)
Phase:
Phase 3
Details
Lead Sponsor:
Peking University
Collaborators:
Chinese PLA General Hospital Peking Union Medical College Hospital Peking University Aerospace Centre Hospital The First Affiliated Hospital of Soochow University Wuhan Union Hospital, China